Upcoming gene therapies for diabetic neuropathy, osteoarthritis and wet age-related macular degeneration are on track for launch in the US within the next three years and have expected patient populations in the multi-millions, which could present a significant challenge for payers, including Medicare and state Medicaid programs.
To date, the individual impact of gene therapies on the market, even with prices that approach and exceed $1m, may...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?